Niveis sericos das imunoglobulinas A G e M em pacientes com cirrose alcoolica compensada e descompensada. / Serum levels of immunoglobulins A,G and M. Nos casos mais graves, ocorre progressão para cirrose e descompensação .. A cirrose compensada é geralmente distinguida da cirrose descompensada por. World Gastroenterology Organisation Global Guidelines. Diagnóstico, tratamento e prevenção da hepatite C. Atualização Equipe de Revisão. Muhammad.

Author: JoJogal Takazahn
Country: Cambodia
Language: English (Spanish)
Genre: Life
Published (Last): 3 January 2011
Pages: 450
PDF File Size: 4.9 Mb
ePub File Size: 12.44 Mb
ISBN: 428-4-91720-706-7
Downloads: 63190
Price: Free* [*Free Regsitration Required]
Uploader: Mikadal

Departamento de Medicina Preventiva e Social.

Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.

To conduct a cost-effectiveness analysis of drug alternatives with rescue therapy in case of relapse due to viral resistance for the treatment of patients with chronic hepatitis B CHB. Hypothetical cohort of patients with CHB, HBeAg-negative, descokpensada clinical or histological evidence of cirrhosis, detectable HBV DNA, histological diagnosis of the disease, positive serum HBsAg for longer than six months, high levels of alanine aminotransferase ALT twice as high as the upper limit of normality and mean age cirroxe 40 years.

Annual rates of disease progression, costs due to complications and the efficacy of medicines were obtained from the literature. One-way and probabilistic sensitivity analysis evaluated uncertainties.

Diagnóstico, tratamento e prevenção da hepatite C

Initiation of treatments with entecavir resulted in an increase of 0. In the probabilistic sensitivity analysis, the acceptability curve showed that descompensaada treatment with entecavir was the most cost-effective alternative in comparison with the use of lamivudine. The availability of entecavir is economically attractive as part of early treatment for patients with chronic hepatitis B without HIV co-infection.


Hepatitis B, Chronic, therapy. Virus de la Hepatitis B, efectos clmpensada drogas. As estimativas de custos foram baseadas em tabelas de pagamento do SUS. Rev Soc Bras Med Trop. Rev Assoc Med Bras. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis.

Secretaria de Estado da Saúde – BVS

Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. EASL clinical practice guidelines. Management of chronic hepatitis B.

Consensus statement short version. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

N Engl J Med. Cirrosd therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. Telbivudine versus lamivudine in patients with chronic hepatitis B. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.


Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. The development of cirrhosis in patients with chronic type B hepatitis: Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan.

J Formos Med Assoc. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A cost-effectiveness desocmpensada of currently approved treatments for HBeAg-positive chronic hepatitis B. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.

Evaluating anti-viral drug selection and fescompensada duration in HBeAg-negative chronic hepatitis B: Alessandra Maciel Almeida Rua Prof. Geneva; [citado Jun 8].

All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. Services on Demand Journal. Taxas de resposta ao tratamento foram assumidas como equivalentes do segundo ao quinto ano para a terapia inicial. How to cite this article.